A Bivalent Bacterium-like Particles-Based Vaccine Induced Potent Immune Responses against the Sudan Virus and Ebola Virus in Mice

被引：2

作者：

Xu, Shengnan ^{[1
,2
,3
]}

Li, Wujian ^{[2
,4
]}

Jiao, Cuicui ^{[4
]}

Cao, Zengguo ^{[2
]}

Wu, Fangfang ^{[2
]}

Yan, Feihu ^{[2
]}

Wang, Hualei ^{[4
]}

Feng, Na ^{[2
]}

Zhao, Yongkun ^{[2
]}

Yang, Songtao ^{[2
]}

Wang, Jianzhong ^{[1
]}

Xia, Xianzhu ^{[1
,2
,5
]}

机构：

[1] Jilin Agr Univ, Coll Vet Med, Changchun, Peoples R China

[2] Chinese Acad Agr Sci, Changchun Vet Res Inst, Changchun, Peoples R China

[3] Shandong Agr Univ, Tai An, Peoples R China

[4] Jilin Univ, Coll Vet Med, Changchun, Peoples R China

[5] Shihezi Univ, Collaborat Innovat Ctr Hlth Sheep Breeding & Zoono, Shihezi, Xinjiang, Peoples R China

来源：

TRANSBOUNDARY AND EMERGING DISEASES | 2023年 / 2023卷

基金：

中国国家自然科学基金;

关键词：

RANDOMIZED-TRIAL; OPEN-LABEL; IMMUNOGENICITY; PROTEIN; SAFETY; ADULTS;

D O I：

10.1155/2023/9248581

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Ebola virus disease (EVD) is an acute viral hemorrhagic fever disease causing thousands of deaths. The large Ebola outbreak in 2014-2016 posed significant threats to global public health, requiring the development of multiple medical measures for disease control. Sudan virus (SUDV) and Zaire virus (EBOV) are responsible for severe disease and occasional deadly outbreaks in West Africa and Middle Africa. This study shows that bivalent bacterium-like particles (BLPs)-based vaccine, SUDV-EBOV BLPs (S/ZBLP + 2 + P), generated by mixing SUDV-BLPs and EBOV-BLPs at a 1 : 1 ratio, is immunogenic in mice. The SUDV-EBOV BLPs induced potent immune responses against SUDV and EBOV and elicited both T-helper 1 (Th1) and T-helper 2 (Th2) immune responses. The results indicated that SUDV-EBOV BLPs-based vaccine has the potential to be a promising candidate against SUDV and EBOV infections and provide a strategy to develop universal vaccines for EVD.

引用

页数：14

共 56 条

[1] Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene A, Gabon: A phase I randomised trial [J].

Agnandji, Selidji T. ;

Fernandes, Jose F. ;

Bache, Emmanuel B. ;

Obiang, Regis M. ;

Brosnahan, Jessica S. ;

Kabwende, Lumeka ;

Pitzinger, Paul ;

Staarink, Pieter ;

Massinga-Loembe, Marguerite ;

Kraehling, Verena ;

Biedenkopf, Nadine ;

Fehling, Sarah Katharina ;

Strecker, Thomas ;

Clark, David J. ;

Staines, Henry M. ;

Hooper, Jay W. ;

Silvera, Peter ;

Moorthy, Vasee ;

Kieny, Marie-Paule ;

Adegnika, Akim A. ;

Grobusch, Martin P. ;

Becker, Stephan ;

Ramharter, Michael ;

Mordmueller, Benjamin ;

Lell, Bertrand ;

Krishna, Sanjeev ;

Kremsner, Peter G. .

PLOS MEDICINE, 2017, 14 (10)

[2] Development of lactococcal GEM-based pneumococcal vaccines [J].

Audouy, Sandrine A. L. ;

van Selm, Saskia ;

van Roosmalen, Maarten L. ;

Post, Eduard ;

Kanninga, Rolf ;

Neef, Jolanda ;

Estevao, Silvia ;

Nieuwenhuis, Edward E. S. ;

Adrian, Peter V. ;

Leenhouts, Kees ;

Hermans, Peter W. M. .

VACCINE, 2007, 25 (13) :2497-2506

[3] Modulation of immune response in Ebola virus disease [J].

Banerjee, Goutam ;

Shokeen, Kamal ;

Chakraborty, Nilanjan ;

Agarwal, Saumya ;

Mitra, Arindam ;

Kumar, Sachin ;

Banerjee, Pratik .

CURRENT OPINION IN PHARMACOLOGY, 2021, 60 :158-167

[4] Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa [J].

Barry, Houreratou ;

Mutua, Gaudensia ;

Kibuuka, Hannah ;

Anywaine, Zacchaeus ;

Sirima, Sodiomon B. ;

Meda, Nicolas ;

Anzala, Omu ;

Eholie, Serge ;

Betard, Christine ;

Richert, Laura ;

Lacabaratz, Christine ;

McElrath, M. Juliana ;

De Rosa, Stephen ;

Cohen, Kristen W. ;

Shukarev, Georgi ;

Robinson, Cynthia ;

Gaddah, Auguste ;

Heerwegh, Dirk ;

Bockstal, Viki ;

Luhn, Kerstin ;

Leyssen, Maarten ;

Douoguih, Macaya ;

Thiebaut, Rodolphe .

PLOS MEDICINE, 2021, 18 (10)

[5] Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice [J].

Bengtsson, Karin Lovgren ;

Song, Haifeng ;

Stertman, Linda ;

Liu, Ye ;

Flyer, David C. ;

Massare, Michael J. ;

Xu, Ren-Huan ;

Zhou, Bin ;

Lu, Hanxin ;

Kwilas, Steve A. ;

Hahn, Timothy J. ;

Kpamegan, Eloi ;

Hooper, Jay ;

Carrion, Ricardo, Jr. ;

Glenn, Gregory ;

Smith, Gale .

VACCINE, 2016, 34 (16) :1927-1935

[6] Structure of the Ebola virus glycoprotein spike within the virion envelope at 11Å resolution [J].

Beniac, Daniel ;

Booth, Timothy F. .

SCIENTIFIC REPORTS, 2017, 7

[7] The Role of Cytokines and Chemokines in Filovirus Infection [J].

Bixler, Sandra L. ;

Goff, Arthur J. .

VIRUSES-BASEL, 2015, 7 (10) :5489-5507

[8] LysM, a widely distributed protein motif for binding to (peptido)glycans [J].

Buist, Girbe ;

Steen, Anton ;

Kok, Jan ;

Kuipers, Oscar R. .

MOLECULAR MICROBIOLOGY, 2008, 68 (04) :838-847

[9] A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates [J].

Callendret, Benoit ;

Vellinga, Jort ;

Wunderlich, Kerstin ;

Rodriguez, Ariane ;

Steigerwald, Robin ;

Dirmeier, Ulrike ;

Cheminay, Cedric ;

Volkmann, Ariane ;

Brasel, Trevor ;

Carrion, Ricardo ;

Giavedoni, Luis D. ;

Patterson, Jean L. ;

Mire, Chad E. ;

Geisbert, Thomas W. ;

Hooper, Jay W. ;

Weijtens, Mo ;

Hartkoorn-Pasma, Jutta ;

Custers, Jerome ;

Pau, Maria Grazia ;

Schuitemaker, Hanneke ;

Zahn, Roland .

PLOS ONE, 2018, 13 (02)

[10] The Application of a Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus [J].

Cao, Zengguo ;

Jin, Hongli ;

Wong, Gary ;

Zhang, Ying ;

Jiao, Cuicui ;

Feng, Na ;

Wu, Fangfang ;

Xu, Shengnan ;

Chi, Hang ;

Zhao, Yongkun ;

Wang, Tiecheng ;

Sun, Weiyang ;

Gao, Yuwei ;

Yang, Songtao ;

Xia, Xianzhu ;

Wang, Hualei .

VIROLOGICA SINICA, 2021, 36 (06) :1648-1651

← 1 2 3 4 5 6 →